William Hiltz is a senior managing director in the firm’s strategic advisory business and head of its special committee practice and board advisory.
Since joining Evercore, Mr. Hiltz has advised General Mills on its acquisition of Pillsbury, the divestiture of its interest in Ice Cream Partners, and the divestiture of its interest in Snack Ventures Europe to PepsiCo.
He has advised CVS on its acquisition of Eckerd, acquisition of Albertson’s free-standing drugstores, and $27 billion merger with Caremark, as well as numerous other deals; EDS on the sale of UGS PLM Solutions and on its $14 billion sale to Hewlett-Packard; Swiss Re on its acquisition of GE’s reinsurance business; Tyco on its split-up into three separately traded companies; Credit Suisse on its sale of Winterthur; Novelis on its sale to Hindalco Industries; Aquila on its sale to Great Plains; GM on its $173 billion restructuring and $23.1 billion initial public offering; Energy Futures Holdings on its $48 billion Chapter 11 reorganization and pending sale of ONCOR for $18.8 billion; CIT on its $54 billion restructuring; the special committee of Affiliated Computer Services on its $8.3 billion sale to Xerox; and BP in its negotiations with the U.S. government concerning the creation and structure of the $20 billion trust fund related to the Gulf of Mexico oil spill.
Other notable deals include advising Kraft on the spinoff of its $36 billion North American grocery business; the special committee of McMoRan Exploration on its $4 billion sale to Freeport-McMoRan; the special committee of Dell on its $24 billion leveraged buyout; the Disinterested Directors of Chrysler Group on the purchase by Fiat of the VEBA’s 41.5% member interests for $3.65 billion; Occidental Petroleum on its $14 billion spinoff of California Resources; CVS Health on its $13 billion acquisition of Omnicare; Broadcom on its $37 billion sale to Avago Technologies; FMC Technologies on its $13 billion merger with Technip; the special committee of Facebook on its $300 billion recapitalization; the special committee of Hilton on the sale of a 25% position to HNA; the special committee of Fortress Investment on the sale to SoftBank; the special committee of Pilgrim’s Pride on its purchase of Moy Park; Whole Foods on its $14 billion sale to Amazon; the board of Aetna on its $77 billion sale to CVS Health; Takeda Pharmaceutical on its $79 billion acquisition of Shire; the special committee of KKR on its conversion to a C Corp; and the special committee of Inovalon on its $7.3 billion sale to Nordic Capital.
Before joining Evercore, Mr. Hiltz was head of the global energy group at UBS Warburg, and prior to UBS’ acquisition of Dillon Read & Co., he was head of the energy group at Dillon Read. Earlier in his career, he was a managing director at Smith Barney, where at various times he headed the energy group, the high-yield and merchant banking group, the transportation group and the general industrial group. He has worked in the investment banking business since 1976, when he first joined Dillon Read.
Mr. Hiltz is a former director of Davis Petroleum and Energy Partners, a former trustee of the Salisbury School, and also served as a trustee of the Lenox Hill Hospital in New York for over 30 years, where he was chairman from 2003 to 2014. He was a trustee and member of the executive committee of the Northwell Health System and currently serves on Northwell’s board of directors. He is a director of the National Park Foundation and its former chairman, and also a member of The Council on Foreign Relations.
He earned a B.A. in history and government from Dartmouth College and an MBA from the University of Pennsylvania’s Wharton School.